Immunomodulatory properties of Enterococcus faecium JWS 833 isolated from duck intestinal tract and suppression of Listeria monocytogenes infection.
The aim of this study was to evaluate the immunomodulatory properties of Enterococcus faecium JWS 833 (JWS 833) isolated from duck intestine and compare them to those of Lactobacillus rhamnosus GG (LGG), a proven immunity-enhancing probiotic. To investigate the immune-enhancing properties of JWS 833, production of nitric oxide (NO) and cytokines was measured in mouse peritoneal macrophages. In addition, a Listeria monocytogenes challenge model was used in the assessment. It was found that heat-killed JWS 833 stimulates mouse peritoneal macrophages to produce NO, interleukin-1 β (IL-1β) and tumor necrosis factor-α (TNF-α) and that oral administration of viable JWS833 enhances NO, IL-1β and TNF-α synthesis upon L. monocytogenes challenge. Moreover, mice fed with JWS 833 were partially protected against lethal challenge with L. monocytogenes. JWS 833 strain has significantly greater immunostimulatory properties than LGG. Moreover, JWS 833 strain partially protects mice against lethal challenge with L. monocytogenes. JWS 833, a novel strain of E. faecium isolated from duck intestine, is potentially a useful feed supplement for controlling pathogens and enhancing host immune responses.
College of Veterinary Medicine and Research Institute of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Korea.
Hyun Jong
HJ
Choi
Myeong Su
MS
Shin
Sang Myeong
SM
Lee
Wan Kyu
WK
Lee
D000818:Animals; D004195:Disease Models, Animal; D004372:Ducks / Q000382:microbiology*; D016984:Enterococcus faecium / Q000276:immunology / Q000302:isolation & purification*; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000276:immunology / Q000628:therapy; D007155:Immunologic Factors / Q000276:immunology / Q000627:therapeutic use*; D053583:Interleukin-1beta / Q000276:immunology; D007422:Intestines / Q000276:immunology / Q000382:microbiology; D008089:Listeria monocytogenes / Q000276:immunology / Q000472:pathogenicity*; D008088:Listeriosis / Q000382:microbiology / Q000628:therapy*; D017737:Macrophages, Peritoneal / Q000276:immunology* / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D050296:Microbial Viability; D009569:Nitric Oxide / Q000276:immunology; D019936:Probiotics / Q000302:isolation & purification / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D007155:Immunologic Factors; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide